Empagliflozyna a zdarzenia sercowo-naczyniowe – wyniki badania EMPA-REG OUTCOME (Kongres EASD 2015)

Bernard Zinman. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med online

Conclusions: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.

The New England Journal of Medicine, 17 września 2015